Latest, results from a phase 1 study with pembrolizumab treatment in programmed cell death ligand -1 (PD-L1) positive PC, showed that the median response treatment time was 13.5 months, progression-free survival and overall survival were 3.5 and 7.9 months, respectively4. Here, CD274 is linked to pachyonychia congenita.